Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist)

Class

fixed-dose combination atypical antipsychotic: olanzapine (broad monoaminergic antagonist at dopamine D1-D4, serotonin 5-HT2A/5-HT2C, muscarinic M1-5, histamine H1, alpha-1 adrenergic receptors) plus samidorphan, a novel mu-opioid receptor antagonist (partial agonist at some G-protein-coupled signaling pathways) added specifically to mitigate olanzapine-associated weight gain; the reference product is Alkermes' Lybalvi, and this entry is Qilu Pharmaceutical's olanzapine-samidorphan tablet in an active Phase 3 trial (vs. olanzapine alone) for the Chinese market

Pathway

olanzapine's dopamine D2 and serotonin 5-HT2A/2C antagonism drives antipsychotic effect on positive and negative symptoms; samidorphan's blockade of mu-opioid receptors (including in the intestinal tract) is thought to help regulate food intake and attenuate olanzapine-induced weight gain without reducing antipsychotic efficacy

This mechanism combines two receptor-blocking actions in a single fixed-dose regimen. The first component is a broad monoaminergic antagonist that blocks dopamine D2 receptors and serotonin 5-HT2A/5-HT2C receptors, among others. Dampening dopamine signaling in specific brain circuits reduces psychotic symptoms such as hallucinations and disorganized thinking, while serotonin receptor blockade is thought to soften motor side effects and contribute to benefit against negative symptoms (blunted emotion, social withdrawal) seen in schizophrenia and related disorders. A well-recognized drawback of this class of antipsychotic is substantial weight gain, driven partly through effects on appetite-regulating circuits and receptors, including histamine and serotonin receptors. The second component addresses this trade-off: it blocks mu-opioid receptors, which participate in reward and appetite regulation both in the brain and in the gut. By antagonizing these receptors, the combination aims to blunt the hyperphagia and metabolic disturbance associated with the antipsychotic component, without diminishing its effect on psychiatric symptoms. This pairing exemplifies a common strategy in drug development: combining an effective but side-effect-prone agent with a second agent chosen specifically to counteract that liability, rather than to add independent therapeutic activity. Such combinations matter broadly in psychiatry, where long-term treatment adherence is often undermined by weight gain and metabolic complications.